Unleashing the power of anti-CD20 immunotherapy: Mitigating multiple sclerosis risk in Epstein-Barr virus latent infections.

Overview of attention for article published in Advances in Clinical and Experimental Medicine, December 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#12 of 658)
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 20 X posts from 20 X users, with an upper bound of 43,327 followers.

RT @Brandon_Beaber: The potential role of EBV and multiple sclerosis and how b-cell depleters (ocrevus, kesimpta, briumvi, rituximab) may w…

RT @Brandon_Beaber: The potential role of EBV and multiple sclerosis and how b-cell depleters (ocrevus, kesimpta, briumvi, rituximab) may w…

RT @Brandon_Beaber: The potential role of EBV and multiple sclerosis and how b-cell depleters (ocrevus, kesimpta, briumvi, rituximab) may w…

RT @Brandon_Beaber: The potential role of EBV and multiple sclerosis and how b-cell depleters (ocrevus, kesimpta, briumvi, rituximab) may w…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 16 additional X posts.